Contineum Therapeutics, Inc. (CTNM)

Compare

6.13

-0.65

(-9.59%)

At close: April 3 at 4:00:01 PM EDT

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

SAN DIEGO, March 17, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025.

Business Wire 17 days ago

CTNM
-9.59%
Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24%

Key Insights Given the large stake in the stock by institutions, Contineum Therapeutics' stock price might be...

Simply Wall St. 22 days ago

CTNM
-9.59%
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

SAN DIEGO, March 12, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18th at 12:30 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum’s website. A w

Business Wire 22 days ago

CTNM
-9.59%
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

SAN DIEGO, March 06, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2024 financial results and affirmed its key clinical development milestones.

Business Wire 28 days ago

CTNM
-9.59%
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

SAN DIEGO, March 04, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today initiated patient dosing in its exploratory PIPE-791 Phase 1b, randomized, double-blind, placebo-controlled, crossover, chronic pain trial. PIPE-791 is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid

Business Wire 30 days ago

CTNM
-9.59%
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

SAN DIEGO, March 03, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Cont

Business Wire last month

CTNM
-9.59%
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

SAN DIEGO, January 08, 2025--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that it has completed the targeted enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial. PIPE-307 is a potentially first-in-class M1 receptor antagonist in development for patients with relapsing-remitting multi

Business Wire 2 months ago

CTNM
-9.59%
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a

GlobeNewswire 2 months ago

RAPT

CTNM
-9.59%
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

SAN DIEGO, December 16, 2024--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced dosing of the first cohort of patients in the PIPE-791 Phase 1b positron emission tomography (PET) trial

Business Wire 3 months ago

CTNM
-9.59%
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

SAN DIEGO, November 25, 2024--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to participate in a fireside chat at the 7th Annual Evercore HealthCONx Con

Business Wire 4 months ago

CTNM
-9.59%
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

SAN DIEGO, November 18, 2024--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced authorization of its Investigational New Drug (IND) application from the U.S. Food and Drug Administrati

Business Wire 4 months ago

CTNM
-9.59%
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 4 months ago

CTNM
-9.59%
Contineum Therapeutics to Attend Upcoming Investor Conferences

SAN DIEGO, November 13, 2024--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to attend the following investor conferences during November 2024.

Business Wire 4 months ago

CTNM
-9.59%
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

SAN DIEGO, November 06, 2024--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate progress.

Business Wire 4 months ago

CTNM
-9.59%
Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28%

Key Insights The considerable ownership by individual investors in Contineum Therapeutics indicates that they...

Simply Wall St. 5 months ago

CTNM
-9.59%
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

SAN DIEGO, August 28, 2024--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced participation in the following upcoming investor conferences:

Business Wire 7 months ago

CTNM
-9.59%
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

SAN DIEGO, August 13, 2024--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress.

Business Wire 7 months ago

CTNM
-9.59%
Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

SAN DIEGO, July 31, 2024--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced encouraging preclinical data on PIPE-307, a potentially first-in-class M1 receptor antagonist in development for patients with relapse

Business Wire 7 months ago

CTNM
-9.59%
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

SAN DIEGO, June 24, 2024--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (Nasdaq: RNA), as an independent me

Business Wire 9 months ago

CTNM
-9.59%
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

SAN DIEGO, June 04, 2024--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that Company management will participate in the 45th Annual Goldman Sachs Healthcare Conference, taking place June 10-13, 2024 in Miam

Business Wire 9 months ago

CTNM
-9.59%

Performance Overview

Return	CTNM	S&P 500 (^GSPC)
YTD	-58.16%	-8.25%
1-Year	-57.72%	+3.55%
3-Year	-57.72%	+18.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Contineum Therapeutics, Inc. (CTNM)

Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24%

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference

Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation

Contineum Therapeutics to Attend Upcoming Investor Conferences

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics, Inc.'s (NASDAQ:CTNM) largest shareholders are individual investors with 41% ownership, institutions own 28%

Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

Performance Overview